BCLI — what changed in the latest 10-Q
A section-by-section comparison of BCLI's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +24 | −20 | ~15 | 104 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~4 | 3 |
| Legal proceedings | Text added/removed | +2 | −3 | ~4 | 2 |
| Risk factors | Some risk factors updated | 0 | 0 | ~2 | 7 |
| Other information | Text added/removed | +4 | −9 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
●On May 21, 2026, the Company filed a Registration Statement on Form S-1 covering the resale of up to 7,796,496 shares of common stock, comprising 1,310,528 outstanding shares of common stock, up to 2,233,334 shares issuable upon the exercise of pre-funded warrants, and up to 4,252,634 shares issuab…
●On May 21, 2026, the Company registered an additional 5,500,000 shares of common stock, par value $0.00005 per share, reserved for issuance under the Company’s 2014 Stock Incentive Plan and 2014 Global Share Option Plan (as amended through February 26, 2026, collectively, the “2014 Plans”). This re…
●On May 25, 2026, the Board of Directors of the Company approved an increase in the number of directors constituting the Board from seven to eight directors and appointed Peter Pitts to serve as a director of the Company, effective as of the same day, to serve until the Company’s 2026 Annual Meeting…
●Jacob Frenkel, Ph.D., resigned as Chairman of the Board and as a director on July 24, 2026. Dr. Frenkel will transition to an advisory role effective immediately to assist with the transition of chairman duties
●On July 24, 2026, the Board of Directors of the Company appointed Peter Pitts, a member of the Board, as Executive Chairman of the Board and Chief Strategic Regulatory Officer. In connection with his appointment, Mr. Pitts and the Company entered into an offer letter dated July 24, 2026, which prov…
Text removed vs the prior filing · source: 10-Q · 2026-05-15
●On July 16, 2025, the Company received a delisting notification from Nasdaq, informing the Company that its common stock will be delisted from The Nasdaq Capital Market. Trading in BrainStorm’s common stock on Nasdaq was suspended at the open of trading on July 18, 2025. The delisting is a result o…
●On July 8, 2025, the Company acknowledged that the FDA consideration of a Citizen Petition requesting a new review of the data supporting NurOwn will provide a critical opportunity to reaffirm its potential as therapy for ALS. A Citizen Petition is a regulatory process that allows any interested pa…
Subsidiary. All granted patents related to NurOwn® (MSC-NTF cells) manufacturing process are fully assigned to or owned by our Israeli Subsidiary (please see Intellectual Property section for details).
was to discuss plans for a SPA with the FDA on the overall protocol design for a planned Phase 3b registrational trial for NurOwn®. The ultimate goal of the SPA is to secure the FDA’s agreement that critical elements of the overall protocol design (e.g., entry criteria, endpoints, planned analyses) …
On August 15, 2022, we announced the decision to submit a BLA to the FDA for NurOwn® for the treatment of ALS. The BLA was filed on September 9, 2022. On November 10, 2022, we announced that we had received a RTF letter from the FDA regarding our BLA for NurOwn® for the treatment of ALS. The FDA inf…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-14
On November 22, 2024, 3D Communications, LLC filed a lawsuit against the Company in the U.S. District Court for the District of Delaware, captioned 3D Communications, LLC v. Brainstorm Cell Therapeutics, Inc. The Complaint asserts a claim for breach of contract and alleges that 3D Communications pro…
On June 18, 2026, Brainstorm Cell Therapeutics Ltd., the Company’s wholly owned Israeli subsidiary, was served with a statement of claim filed by Sourasky University Medical Center (“Ichilov”) in the Magistrates’ Court of Tel Aviv-Jaffa. The claim alleges breach of an agreement for the use of clean …
Text removed vs the prior filing · source: 10-Q · 2026-05-15
On December 31, 2025, a purported shareholder of the Company filed a complaint pursuant to 8 Del. C. § 220 in the Delaware Court of Chancery, captioned Roth v. BrainStorm Cell Therapeutics, Case No. 2025-1507, seeking inspection of certain books, records, and documents of the Company. The matter is …
The Company intends to vigorously defend against these lawsuits. On November 22, 2024, 3D Communications, LLC filed a lawsuit against the Company in the U.S. District Court for the District of Delaware, captioned 3D Communications, LLC v. Brainstorm Cell Therapeutics, Inc., Case No. 1:24-cv-01286. T…
close on May 15, 2026, with depositions of Company representatives to be taken in May 2026. 3D Communications, LLC seeks monetary damages relating to the master services agreement and statement of work, as well as attorneys’ fees and costs.
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-14
On July 6, 2026, the Company issued an unsecured convertible promissory note (the “July 6 Note”) in the principal amount of $151,800, receiving $125,000 in cash proceeds after an original issue discount of $19,800. The July 6 Note carries a 12% one-time interest charge, matures in 12 months, and req…
The July 2 Note and the July 6 Note were sold in reliance upon an exemption from the registration requirement of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder.
The disclosure set forth in this Item 5 is intended to satisfy the Company’s disclosure obligations under Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant), and Item 3.…
During the quarter ended June 30, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).
Text removed vs the prior filing · source: 10-Q · 2026-05-15
On May 11, 2026, the Company entered into a securities purchase agreement pursuant to which it issued a promissory note (the “Note”) to an institutionalinvestor. The transaction was entered into in reliance upon exemptions from registration requirent under the Securities Act of 1933, as amended.
The Note has the aggregate principal amount of $151,800 (including $19,800 original issue discount) for aggregate purchase price proceeds of $132,000, and with the agreement contemplating additional tranches of up to $2,000,000 subject to further agreement. The note bears a one-time interest charge …
The Note, and the shares of the Company’s common stock issuable upon conversion of the Note, if any, were or will be issued in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D thereunder. The investors represented that th…
On May 11, 2026, the Company entered into two separate Securities Purchase Agreements (collectively, the “May 2026 SPAs”) with two accredited investors, pursuant to which the Company agreed to issue and sell, in private placement transactions, (i) an aggregate of 210,526 shares (the “Shares”) of the…
The purchase price was $0.95 per Share. The Common Warrants have an exercise price of $1.45 per share, are exercisable immediately upon issuance and expire five (5) years from the date of issuance. The exercise price of, and the number of shares of Common Stock issuable upon exercise of, the Common …
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice